Drug discovery quarterly review: Second quarter 2023
Drug Discovery World
SEPTEMBER 14, 2023
Total revenue from oncology medicines increased 22%, CVRM 20%, R&I8 10%, and rare disease 12%. Vaccines were up 9.1% Moreover, in July 2023, AstraZeneca and Vaxess Technologies commenced a collaboration for the evaluation of a novel RNA-based pandemic influenza prototype vaccine in patch format. Chris Boshoff, M.D.,
Let's personalize your content